Next Article in Journal
Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro
Previous Article in Journal
Distribution of Human Papillomavirus (HPV) Genotypes in HIV-Negative and HIV-Positive Women with Cervical Intraepithelial Lesions in the Eastern Cape Province, South Africa
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Viruses
Volume 13
Issue 2
10.3390/v13020281
viruses-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients

by
Mattia Trunfio
1,*,
Francesco Venuti
1,
Francesca Alladio
1,
Bianca Maria Longo
1,
Elisa Burdino
2,
Francesco Cerutti
2,
Valeria Ghisetti
2,
Roberto Bertucci
1,
Carlo Picco
3,
Stefano Bonora
1,
Giovanni Di Perri
1,3 and
Andrea Calcagno
1
1
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino at the Amedeo di Savoia Hospital, Corso Svizzera 164, 10149 Torino, Italy
2
Microbiology and Molecular Biology Laboratory, Amedeo di Savoia Hospital, ASL Città di Torino, Corso Svizzera 164, 10149 Torino, Italy
3
Regional Department for Infectious Diseases and Emergency DIRMEI, ASL Città di Torino, Via S. Secondo 29, 10128 Torino, Italy
*
Author to whom correspondence should be addressed.
Viruses 2021, 13(2), 281; https://doi.org/10.3390/v13020281
Submission received: 11 January 2021 / Revised: 8 February 2021 / Accepted: 9 February 2021 / Published: 11 February 2021
(This article belongs to the Section SARS-CoV-2 and COVID-19)
Browse Figure
Review Reports Versions Notes

Abstract

To date, there is no severe acute respiratory syndrome coronavirus 2-(SARS-CoV-2)-specific prognostic biomarker available. We assessed whether SARS-CoV-2 cycle threshold (Ct) value at diagnosis could predict novel CoronaVirus Disease 2019 (COVID-19) severity, clinical manifestations, and six-month sequelae. Hospitalized and outpatient cases were randomly sampled from the diagnoses of March 2020 and data collected at 6 months by interview and from the regional database for COVID-19 emergency. Patients were stratified according to their RNA-dependent-RNA-polymerase Ct in the nasopharyngeal swab at diagnosis as follows: Group A ≤ 20.0, 20.0 < group B ≤ 28.0, and Group C > 28.0. Disease severity was classified according to a composite scale evaluating hospital admission, worst oxygen support required, and survival. Two hundred patients were included, 27.5% in Groups A and B both, 45.0% in Group C; 90% of patients were symptomatic and 63.7% were hospitalized. The median time from COVID-19 onset to swab collection was five days. Lethality, disease severity, type, and number of signs and symptoms, as well as six-month sequelae distributed inversely among the groups with respect to SARS-CoV-2 Ct. After controlling for confounding, SARS-CoV-2 Ct at diagnosis was still associated with COVID-19-related death (p = 0.023), disease severity (p = 0.023), number of signs and symptoms (p < 0.01), and presence of six-month sequelae (p < 0.01). Early quantification of SARS-CoV-2 may be a useful predictive marker to inform differential strategies of clinical management and resource allocation.
Keywords: COVID-19; viral load; sequelae; outcomes; cycle threshold; severity; mortality; SARS-CoV-2 swab; predictive biomarker COVID-19; viral load; sequelae; outcomes; cycle threshold; severity; mortality; SARS-CoV-2 swab; predictive biomarker

Share and Cite

MDPI and ACS Style

Trunfio, M.; Venuti, F.; Alladio, F.; Longo, B.M.; Burdino, E.; Cerutti, F.; Ghisetti, V.; Bertucci, R.; Picco, C.; Bonora, S.; et al. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses 2021, 13, 281. https://doi.org/10.3390/v13020281

AMA Style

Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, et al. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses. 2021; 13(2):281. https://doi.org/10.3390/v13020281

Chicago/Turabian Style

Trunfio, Mattia, Francesco Venuti, Francesca Alladio, Bianca Maria Longo, Elisa Burdino, Francesco Cerutti, Valeria Ghisetti, Roberto Bertucci, Carlo Picco, Stefano Bonora, and et al. 2021. "Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients" Viruses 13, no. 2: 281. https://doi.org/10.3390/v13020281

APA Style

Trunfio, M., Venuti, F., Alladio, F., Longo, B. M., Burdino, E., Cerutti, F., Ghisetti, V., Bertucci, R., Picco, C., Bonora, S., Di Perri, G., & Calcagno, A. (2021). Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses, 13(2), 281. https://doi.org/10.3390/v13020281

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop